<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="4444" end="4449" sStart="4387" offset="57" sid="r7.1.use.v.0396" wn="1" wnkey="use%2:34:01::" annotator="cgozo" text="The cells were then harvested on filter papers using a harvester, filter papers were dried and were then transferred to liquid scintillation vials and [ 3H] thymidine uptake were quantified as counts per minute (CPM) using a liquid scintillation counter." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-9433-1-3.anc" start="4512" end="4523" sStart="null" offset="0" sid="null" wn="2" wnkey="transfer%2:40:01::" annotator="carichter" text="The cells were then harvested on filter papers using a harvester, filter papers were dried and were then &lt;b&gt;transferred&lt;/b&gt; to liquid scintillation vials and [ 3H] thymidine uptake were quantified as counts per minute (CPM) using a liquid scintillation counter." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-9433-1-3.anc" start="13808" end="13812" sStart="null" offset="0" sid="null" wn="1" wnkey="part%1:24:00::" annotator="carichter" text="These results demonstrate that decreased lymphocyte proliferation in &lt;b&gt;part&lt;/b&gt; may be due to increased levels of TGF-? in these patients." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="8842" end="8847" sStart="null" offset="77" sid="null" wn="1" wnkey="level%1:07:00::" annotator="veweser" text="The TAC dose was not adjusted during the study period and mean TAC level at 14 days was 6 ng/ml (4-13 ng/ml)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="8842" end="8847" sStart="null" offset="77" sid="null" wn="1" wnkey="level%1:07:00::" annotator="sophiavv" text="The TAC dose was not adjusted during the study period and mean TAC level at 14 days was 6 ng/ml (4-13 ng/ml)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="8842" end="8847" sStart="null" offset="77" sid="null" wn="1" wnkey="level%1:07:00::" annotator="cgozo" text="The TAC dose was not adjusted during the study period and mean TAC level at 14 days was 6 ng/ml (4-13 ng/ml)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="8842" end="8847" sStart="null" offset="77" sid="null" wn="1" wnkey="level%1:07:00::" annotator="brubin" text="The TAC dose was not adjusted during the study period and mean TAC level at 14 days was 6 ng/ml (4-13 ng/ml)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="9027" end="9033" sStart="null" offset="14" sid="r9.level.n.0728" wn="2" wnkey="level%1:26:01::" annotator="brubin" text="The exact SRL levels were not available as they were processed in central core laboratories, however were maintained at therapeutic level." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="8842" end="8847" sStart="null" offset="77" sid="null" wn="" wnkey="null" annotator="bpassonneau" text="The TAC dose was not adjusted during the study period and mean TAC level at 14 days was 6 ng/ml (4-13 ng/ml)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="8842" end="8847" sStart="null" offset="77" sid="null" wn="2" wnkey="level%1:26:01::" annotator="anfahmy" text="The TAC dose was not adjusted during the study period and mean TAC level at 14 days was 6 ng/ml (4-13 ng/ml)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="3084" end="3092" sStart="null" offset="158" sid="r11.function.n.0460" wn="2" wnkey="function%1:07:00::" annotator="vebatchelder" text="The graphic representation of the treatment protocol is shown in figure 1. The effect of this concomitant therapy on the immune function was studied by quantifying lymphocyte proliferation and the mRNA expression of TGF-?, TNF-?, IL-10, IL-6, IFN-? by RT-PCR assay." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="12435" end="12446" sStart="null" offset="0" sid="r11.combination.n.0907" wn="1" wnkey="combination%1:14:00::" annotator="vebatchelder" text="Combination of decreased expression of cyclin and increased p21 mRNA expression correlates with the decreased lymphocyte proliferation." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="1084" end="1095" sStart="null" offset="145" sid="r11.combination.n.0637" wn="1" wnkey="combination%1:14:00::" annotator="vebatchelder" text="However, experimental and clinical studies have refuted this assumption, and have successfully demonstrated the efficacy of this combination therapy [ 8 9 10 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="1630" end="1641" sStart="null" offset="159" sid="r11.combination.n.0511" wn="1" wnkey="combination%1:14:00::" annotator="vebatchelder" text="A total of 10 stable renal transplant recipients were selected to participate in a pharmacokinetic (PK) and immune function study with combination of TAC and SRL therapy in human transplant." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="15067" end="15078" sStart="null" offset="63" sid="r11.combination.n.0962" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="Recently [ 11 ] , we have demonstrated the efficacy of combination of low doses of SRL with either CsA or TAC to inhibit lymphocyte proliferation." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="14849" end="14860" sStart="null" offset="128" sid="r11.combination.n.0869" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="However, recent experimental and clinical studies have refuted this assumption, and have successfully used this combination therapy [ 8 9 10 ] . Therefore there is need of an alternate strategy to use these drugs to treat renal transplant recipients." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="15986" end="15997" sStart="null" offset="115" sid="r11.combination.n.0713" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="Such a sustained effect is expected to prevent graft rejection, demonstrating the efficacy of this combination in renal transplant recipients." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="19232" end="19243" sStart="null" offset="134" sid="r11.combination.n.0437" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="Though the role of TGF-? has been correlated with drug induced nephrotoxicity [ 29 ] it is early to speculate if this combination will also result in an increased nephrotoxic effects." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="12688" end="12699" sStart="null" offset="0" sid="r11.combination.n.0371" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="Combination of TAC and SRL resulted in a significant inhibition of cytokines in sera of patients compared to patients treated with TAC/MMF/Aza." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="13331" end="13342" sStart="null" offset="128" sid="r11.combination.n.0066" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="Since we observed a significant increase in TGF-? mRNA expression in lymphocytes from patients treated with combination of TAC and SRL compared to TAC/MMF/Aza, we also studied circulating levels of total TGF-? protein in acid activated sera from these patients." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="19372" end="19383" sStart="null" offset="66" sid="r11.combination.n.0489" wn="1" wnkey="combination%1:14:00::" annotator="adelpriore" text="We are unable to demonstrate the nephrotoxicity with this combination due to short course of therapy." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="1825" end="1836" sStart="null" offset="139" sid="r11.combination.n.0360" wn="7" wnkey="combination%1:04:00::" annotator="adelpriore" text="The current study describes the analysis of immune function in stable renal transplant recipients with SRL and TAC combination therapy." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="19873" end="19884" sStart="null" offset="91" sid="r11.combination.n.0240" wn="7" wnkey="combination%1:04:00::" annotator="adelpriore" text="In conclusion, these results provide evidence to potential efficacy of TAC and SRL combination therapy in renal transplant recipients." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-9433-1-3.anc" start="13331" end="13342" sStart="null" offset="128" sid="r11.combination.n.0066" wn="1" wnkey="combination%1:14:00::" annotator="adelpriore" text="Since we observed a significant increase in TGF-? mRNA expression in lymphocytes from patients treated with combination of TAC and SRL compared to TAC/MMF/Aza, we also studied circulating levels of total TGF-? protein in acid activated sera from these patients." />
  </sentences>
</list>